KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accounts Payables (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Accounts Payables for 17 consecutive years, with $759.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 25.05% year-over-year to $759.0 million, compared with a TTM value of $759.0 million through Dec 2025, up 25.05%, and an annual FY2025 reading of $759.0 million, up 25.05% over the prior year.
  • Accounts Payables was $759.0 million for Q4 2025 at Biomarin Pharmaceutical, down from $798.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $798.4 million in Q3 2025 and bottomed at $411.1 million in Q2 2021.
  • Average Accounts Payables over 5 years is $590.0 million, with a median of $597.2 million recorded in 2023.
  • The sharpest move saw Accounts Payables skyrocketed 40.29% in 2023, then decreased 11.15% in 2024.
  • Year by year, Accounts Payables stood at $498.3 million in 2021, then grew by 14.99% to $573.0 million in 2022, then increased by 19.23% to $683.1 million in 2023, then fell by 11.15% to $607.0 million in 2024, then rose by 25.05% to $759.0 million in 2025.
  • Business Quant data shows Accounts Payables for BMRN at $759.0 million in Q4 2025, $798.4 million in Q3 2025, and $684.2 million in Q2 2025.